DiaMedica Therapeutics Inc. Cash and Cash Equivalents, Period Increase (Decrease)
DiaMedica Therapeutics Inc. (DMAC) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$583.00 thousand for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-13.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2020-05-13
- DiaMedica Therapeutics Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2020-03-31 was -$583.00K.
- DiaMedica Therapeutics Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-12-31 was -$858.00K, a 106.64% decline year-over-year.
- DiaMedica Therapeutics Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-09-30 was $1.77M.
- DiaMedica Therapeutics Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was $215.00K.
- DiaMedica Therapeutics Inc. cash and cash equivalents, period increase (decrease) for fiscal 2019 was -$12.94M, a 183.65% decline from fiscal 2018.
- DiaMedica Therapeutics Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $15.47M.
- DiaMedica Therapeutics Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$383.00K.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2020-03-31 | -$583.00K 10-Q · filed 2020-05-13 | -$1.44M derived: sum of 2 quarters · filed 2020-05-13 | $326.00K derived: sum of 3 quarters · filed 2020-05-13 | $541.00K derived: sum of 4 quarters · filed 2020-05-13 |
| 2019-12-31 | -$858.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | $909.00K derived: sum of 2 quarters · filed 2020-03-23 | $1.12M derived: sum of 3 quarters · filed 2020-03-23 | -$12.94M 10-K · filed 2020-03-23 |
| 2019-09-30 | $1.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $1.98M derived: sum of 2 quarters · filed 2019-11-13 | -$12.08M 10-Q · filed 2019-11-13 | $843.00K derived: sum of 4 quarters · filed 2020-05-13 |
| 2019-06-30 | $215.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | -$13.85M 10-Q · filed 2019-08-13 | -$924.00K derived: sum of 3 quarters · filed 2020-05-13 | -$2.75M derived: sum of 4 quarters · filed 2020-05-13 |
| 2019-03-31 | -$14.06M 10-Q · filed 2020-05-13 | -$1.14M derived: sum of 2 quarters · filed 2020-05-13 | -$2.97M derived: sum of 3 quarters · filed 2020-05-13 | -$3.95M derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | $12.93M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | $11.10M derived: sum of 2 quarters · filed 2020-03-23 | $10.11M derived: sum of 3 quarters · filed 2020-03-23 | $15.47M 10-K · filed 2020-03-23 |
| 2018-09-30 | -$1.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | -$2.81M derived: sum of 2 quarters · filed 2019-11-13 | $2.54M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | -$984.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $4.37M 10-Q · filed 2019-08-13 | ||
| 2018-03-31 | $5.36M 10-Q · filed 2019-05-13 | |||
| 2017-12-31 | -$383.00K 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |